A Clinical Trial to Investigate the Safety and Efficacy of AP-Brain on Cognitive Function at Varying Dosages in Healthy Younger Adults With Self-reported Attention Problems

Inclusion criteria

• ✓. Males and females 18-39 years of age, inclusive
• ✓. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening
• ✓. Individuals with self-reported focus or attention problems, as determined by QI assessment of the Adult Attention Deficit Hyperactivity Disorder Self-Report Scale (Part A) (ASRS; version 1.1) (20)
• ✓. Agrees to avoid high sources of caffeine (e.g., supplements, tea, coffee, energy drinks), NSAIDs, and alcohol consumption for 24 hours prior to post-screening clinic visits
• ✓. Agrees to avoid first generation anti-allergy medication for 48 hours prior to post-screening clinic visits
• ✓. Agrees to avoid moderate-vigorous exercise 12 hours prior to post-screening clinic visits
• ✓. Agrees to avoid travel across two or more time zones two weeks prior to any study visit
• ✓. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study

Exclusion criteria